Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of BAY1830839 in healthy men
NCT03540615Phase 1Completed
- Sponsor
- Bayer
- Start
- Jun 2018
- Primary completion
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in rheumatoid arthritis (RA) comparing BAY1830839 with Placebo (2 arms). Primary endpoints: Area Under the Curve of BAY1830839 in plasma at Day 12, Maximum observed drug concentration of BAY1830839 in plasma at Day 12 and 2 more. Started Jun 2018; status: completed.
02
Drugs
BAY1830839
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT03540615.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03540615.